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Catalytic N-dealkylation of Pharmaceuticals on 
Nanoporous Gold in a Continuous Flow System 
Continuous-flow systems are widely applied in synthetic organic chemistry. The fast 
mass transfer and mixing in a flow reactor opens new possibilities for organic 
synthesis. In this study, we report a continuous-flow system with nanoporous gold 
as a catalyst that allows the selective conversion of lidocaine and metoprolol to their 
N-dealkylation products, and the N-demethylation of atropine to noratropine. This 
continuous-flow system is promising for upscaling N-dealkylation reactions for the 
synthesis of drug metabolites or added value precursors of pharmaceutical products. 
  






Recently, continuous-flow systems have attracted considerable attention for the 
synthesis of complex organic molecules, for example, active pharmaceutical 
ingredients (APIs) or natural products [1, 2]. Owing to the small dimensions of 
continuous-flow systems, mass transfer and heating are much more efficient than in 
batch systems. Moreover, hazardous or toxic reaction products that may pose safety 
hazards when operating in a batch system can be handled more safely [3]. In another 
aspect, reaction processes have more flexibility in a flow system, where different 
parameters, such as temperature, flow rate, and pressure can be controlled more 
precisely [4].  
Pharmaceuticals can be N-dealkylated in vivo by members of the cytochrome 
P450 enzyme family as part of Phase-I metabolism [5, 6], or by conventional organic 
synthesis methods. However, the subsequent purification processes are usually 
costly and time-consuming [7]. In addition, they often require toxic reagents that 
pose a threat for the environment. There is thus a need to develop sustainable 
methods for the selective conversion of pharmaceuticals to high-value N-
dealkylation product, for example, conversion of atropine to noratropine.  
Nanoporous gold (NPG), prepared by chemical etching of alloys in concentrated 
nitric acid, displays a sponge-like structure with pore sizes ranging from a few 
nanometers to a few micrometers [8], depending on the alloy and etching time. NPG 
has been shown to be an efficient catalyst for the oxidation of, for example, CO [9], 
methanol [10], ethanol [11], and glucose [12]. In addition, NPG can be easily 
produced and reused, making it interesting for production up-scaling. Recently, we 
reported the selective N-dealkylation of lidocaine and metoprolol with yields above 
90% in a batch system at 60 °C under conditions of air purging [13]. Of note, no 
other side products were observed, such as N-oxides or hydroxylation products, 
demonstrating the high selectivity of the NPG-mediated reactions.  
Batch systems, rather than continuous-flow systems, are widely used for fine 
chemicals production, and the synthesis of more complex molecules, such as drugs, 
in a continuous-flow system, proved difficult [4b, 14]. Heterogeneous catalysts such 
as NPG are ideally suited for flow systems provided they are highly selective [1a]. 
In this work, we designed a continuous-flow system for the N-dealkylation of 






dealkylation of lidocaine and metoprolol was achieved. In addition, the selectivity 
of the N-demethylation of atropine to noratropine over formation of the N-formyl 
by-product was improved from 25% in a batch system to 88% in the continuous-
flow system. All reactions were performed in water, making this an environmental-
friendly approach that is amenable for further up-scaling. 
6.2 Experimental Section  
Materials. HNO3 (69 %), lidocaine, metoprolol and atropine were purchased from 
Sigma-Aldrich. A 10×10×0.5 mm piece of 99.99 % gold sheet and 585 gold alloy 
sheet containing 58.5% gold, 30% silver and 11.5% other non-noble metals was 
purchased from Heraeus (Hanau, Germany). Water was purified by a Milli-Q 
Advantage A10 system (Merck Millipore, Billerica, USA). Ultrapure HPLC grade 
acetonitrile was purchased from Biosolve Chimie (Dieuze, France). Acetone (AR) 
was purchased from Biosolve BV (Valkenswaard, the Netherlands), and H2SO4 
(98%) was purchased from Merck (Darmstadt, Germany). The flow-through cell 
(Flexcell) was purchased from Antec Leyden (Zoeterwoude, the Netherlands). 
Preparation of the catalytic nanoporous gold (NPG) surface. The catalytic NPG 
surface was prepared from the gold alloy by etching in concentrated nitric acid for 
24 h, followed by thorough washing with deionized water and acetone. The NPG 
was subsequently cut to fit the dimensions of the Flexcell. 
Sample preparation. For catalytic conversions in a continuous-flow reactor, 
solutions of lidocaine, metoprolol and atropine were prepared at 1 µM in water, and 
purged with air for 15 min in a 4 mL glass vial to ensure oxygen saturation. The 
samples were subsequently pumped through the Flexcell at different flow rates using 
a peristaltic pump at 60 °C. For the turnover frequency study, 1 mL samples with 
different compound concentrations were incubated with NPG under air purging in a 
4 mL glass vial. The catalysis samples of lidocaine and metoprolol were prepared by 
incubation with NPG at 60 °C for 30 min with air purging.  
LC-MS/MS analysis. Samples of lidocaine and metoprolol prepared in the Flexcell 
were analyzed by LC-MS/MS in a system consisting of an Ultimate plus HPLC 
(Thermo Scientific, Sunnyvale, United States) coupled to an API 365 triple 
quadrupole mass spectrometer (MDS Sciex, Concord, Canada) operated in positive 
electrospray ionization mode. MS/MS parameters were as follows: ion spray voltage 





5000 V, ring (RNG) voltage 170 V, orifice (OR) 40 V, and collision energy 20 eV. 
A flow rate of 1 L/min nitrogen at 450 °C was used.The product ion scan range was 
m/z 70 to 700 with step size 1.0 amu and a dwell time of 1 ms. A C18 reversed-phase 
column (GraceSmart RP 18 5 μm, 2.1×150 mm Grace Davison, Lokeren, Belgium) 
was used throughout the experiments at a flow rate of 250 μL/min. Solvent A: H2O 
with 0.1 % formic acid; solvent B: ACN with 0.1 % formic acid. A linear gradient 
of 20-50 % B in 10 min was used for elution with 40 μL injections of the diluted 
samples.  
Samples for the turnover frequency study were analyzed by LC-MS/MS in a system 
consisting of an Ultimate plus HPLC (Thermo Scientific, Sunnyvale, United States) 
coupled to a TSQ Quantum AM triple quadrupole mass spectrometer with an ESI 
interface in the positive mode (Thermo Finnnigan, San Jose, CA). MS/MS 
parameters were as follows: spray voltage 4000 V, auxiliary gas pressure 20, sheath 
gas pressure 40, capillary temperature 350 °C, tube lens offset 90 V, skimmer offset 
0 V. The product ion scan range was from m/z 50 to 350, with a scan time of 1 s and 
Q1 and Q3 at 0.7 FWHM. For the selected reaction monitoring (SRM) analysis, two 
transitions were used for lidocaine (235/86) and the N-dealkylation product (207/58), 
two transitions for metoprolol (268/116) and the N-dealkylation product (226/121), 
three transitions for atropine (290/124), nor-atropine (276/110) and N-formyl-
noratropine (304/138). A dwell time of 100 ms was used for each transition. 
Scanning electron microscopy (SEM). SEM characterization of the NPG surfaces 
was performed on a Philips XL-30S SEM FEG system (Amsterdam, the Netherlands) 
at 30 kV. 
6.3 Results and Discussions 
6.3.1 Continuous-flow system 
Figure 1a shows the continuous-flow reactor. The Flexcell, which is normally used 
for electrochemical detection and conversion reactions, was used as a continuous-
flow system with the NPG mounted in place of the working electrode. The system 
was not connected to a potentiostat. NPG was prepared by chemical etching of a 
gold/silver alloy in concentrated nitric acid for 24 h as reported before [9]. The NPG 
has a homogeneous continuous 3D structure with an average pore diameter of 35 nm 






spacer of 50 µm thickness with a lozenge-shaped hole, so that an NPG flow chamber 
of approximately 500 nL is formed between the spacer and the NPG (Figure 1b). For 
temperature control, the cell was placed in an oven at a temperature of 60 °C, which 
proved optimal during previous batch experiments [13]. Prior to the reaction, the 
sample solution was purged with air for 15 min in a 4 mL glass vial to ensure the 
sample was saturated with oxygen, since the N-dealkylation reaction was shown to 
be an oxygen-dependent reaction [13]. The sample solution was pumped through the 
flow cell at flow rates ranging from 1 to 25 µL/min. Fractions were collected at the 
outlet of the flow reactor at different time points for LC-MS/MS analysis. 
 
Figure 1. Continuous flow system for the N-dealkylation of lidocaine, metoprolol and 
atropine; schematic drawing (a); nanoporous gold (NPG) catalysis flow chamber (b); 
scanning electron microscopy (SEM) image of NPG surface at a magnification of 
50000 (c). 
6.3.2 Catalytic N-dealkylation of lidocaine in the continuous-flow system 
The catalytic activity of NPG in a flow cell system was first evaluated using lidocaine, 
a drug molecule that has been thoroughly investigated before in our lab [15]. 
Lidocaine was shown to be N-dealkylated on NPG in a batch cell under conditions 
of air purging at 60 °C [13]. As shown in Figure 2b, the N-dealkylation yield of 
lidocaine was 82% (by using a synthetic standard) at flow rate of 1 μL/min under air 
purging. Taking into account that the internal volume of the continuous-flow system 





is 500 nL, the residence time of the lidocaine solution on the NPG surface is only 30 
s, demonstrating the fast kinetics of the N-dealkylation reaction on NPG. In addition, 
only the N-dealkylation product (m/z 207) was observed, and no other side products 
were detected, such as the N-oxide (m/z 251), the di-dealkylation product or 
diethylamine.  
Figure 2c shows that the yield of N-dealkylated lidocaine decreased to 15% when 
increasing the flow rate to 20 μL/min (calculated contact time of 1.5 s). The 
decreasing yield at higher flow rates may be due to mass transfer limitations [3]. N-
dealkylation of lidocaine reached 93% in a batch cell after 1.5 h while it took only 
30 s contact time in a flow system to reach a yield of 82%. It is thus likely that flow 
systems with contact times of a few minutes would be sufficient to give complete 
conversion of lidocaine. This can, for example, be achieved using longer flow paths. 
It is interesting to note that an N-dealkylation yield of 15% was observed at 25 
μL/min. It is currently unclear why the yield does not decrease any further despite 
the fact that contact times are very short. Further work at higher flow rates is needed 
to elucidate this phenomenon. It is expected that the yield will approximate 0 as flow 
rates are further increased, since the residence time of lidocaine will be so short that 








Figure 2. Catalytic N-dealkylation of lidocaine (1 µM in water) on an NPG surface in 
a flow cell. a) The N-dealkylation reaction of lidocaine; b) LC-MS/MS analysis of the 
sample at a flow rate of 1 μL/min at 60 °C with air purging, N-dealkylated lidocaine 
(m/z 207, red trace), lidocaine (m/z 235, black trace); c) Flow rate dependence of 
the catalytic N-dealkylation yield of lidocaine. Each sample was prepared and 
analyzed three times. 
6.3.3 Catalytic N-dealkylation of metoprolol in the continuous-flow system 
Metoprolol, which has a secondary amine, as well as groups that are amenable to O-
dealkylation, was also evaluated on the flow cell system. This compound was 
converted to 99% of the N-dealkylated form in a batch cell after 2 h with air purging 
at 60 °C by loss of an isopropyl group as reported earlier [13]. When 1 µM sample 
was pumped through the NPG cell at a flow rate of 1 μL/min, metoprolol was 
converted to the N-dealkylation product (m/z 226) with an estimated yield of 48% 
by comparing the integrated peak areas. Only N-dealkylation occurred on the NPG 





in the flow system, with no side reactions such as O-dealkylation, aromatic 
hydroxylation or isopropylamine formation. Figure 3c shows the flow rate 
dependence of the N-dealkylation yield of metoprolol, which decreases from 48% at 
1 μL/min to 10% at 25 μL/min, slightly lower than for lidocaine. 
 
Figure 3. Catalytic N-dealkylation of metoprolol (1 µM in water) on an NPG surface. 
a) The N-dealkylation reaction of metoprolol; b) LC-MS/MS analysis at a flow rate of 
1 μL/min at 60 °C with air purging (metoprolol, m/z 268, black trace, N-dealkylation 
product, m/z 226, red trace); c) Flow rate dependence of the N-dealkylation yield of 
metoprolol. Each sample was prepared and analyzed three times. 
6.3.4 Catalytic N-dealkylation of atropine in the continuous-flow system 
To assess the scope of N-dealkylation reactions that can be catalyzed by NPG, we 
investigated the conversion of a complex natural product atropine, which contains a 






atropine to nor-atropine (m/z 276) reached a maximum after 7 h incubation at 60 °C 
with air purging (Figure S1b). Using synthetic nor-atropine as a standard, we 
confirmed its identity in the reaction mixture by co-elution and high-resolution 
MS/MS (Figure S1a, S1c). Another product N-formyl-noratropine (m/z 304) was 
also observed (Figure S2). The ratio of nor-atropine to N-formyl-noratropine on 
NPG was only 25%. In order to confirm the identity of N-formyl-noratropine, we 
synthesized N-formyl-noratropine by following a protocol reported before [16], and 
its structure was confirmed by MS/MS analysis (Figure S2). Of note, when 
performing the experiment in the continuous-flow system, the selectivity of N-
dealkylation of atropine was highly improved to 88% (Figure 4b), possibly due to 
the short residence time in the flow reactor, so that the side product of N-formyl-
noratropine is more difficult to form. This gave new insights for the further 
application of such a continuous flow system, especially for the improved selectivity 
synthesis of noratropine. 
 
Figure 4. Catalytic N-dealkylation of atropine (1 µM in water) on an NPG surface. a) 
The N-dealkylation reaction of atropine; b) LC-MS/MS analysis at a flow rate of 1 
μL/min at 60 °C with air purging (atropine, m/z 290, black trace; N-dealkylation 
product (nor-atropine), m/z 276, red trace; N-formyl-noratropine, m/z 304, blue trace).  






In summary, a continuous-flow system with NPG as catalyst was designed for the 
highly selective N-dealkylation of lidocaine, metoprolol. Of note, the formation of 
N-formyl-noratropine, a major by-product of the batch reaction, was greatly reduced 
in the continuous flow system probably due to the short residence time. The 
continuous-flow system had a fast response and was easy to handle, which makes it 
particularly suitable for screening reaction conditions prior to scaling up. While the 
volume of the continuous flow system was just 500 nL, it has been shown that flow 
systems can be scaled up by tuning dimensions [17]. Continuous flow systems 
containing an NPG catalyst are of interest for the synthesis of N-dealkylation 
metabolites of pharmaceuticals and the production of added value intermediates 








Figure. S1. Catalytic N-dealkylation of 100 µM atropine in water on an NPG surface 
at 60 °C with air purging. a) Fragment assignment of the N-dealkylation product (nor-
atropine) in Figure S2c; b) LC-MS/MS analysis after 7 h incubation (atropine black 
trace, N-dealkylation product red trace, N-formyl-noratropine blue trace); c) High-
resolution MS/MS spectra of N-dealkylation product of atropine. 
  





Synthesis of N-formyl-noratropine. N-formyl-noratropine was synthesized as 
described elsewhere [16]. Briefly, 30 μL HCOOH was added to 1 mL CH2Cl2 on an 
ice bath under stirring, then 0.08 mg EDC was added and mixed for 15 min. After 
that, 0.11 mg nor-atropine and 0.04 mg N-methymorpholine was added, and stirred 
for 1 day. The sample was diluted 400 times in water for product ion scan analysis 
by direct infusion on API 365 triple quadrupole mass spectrometer.  
 
Figure. S2. Left: LC-MS/MS analysis of synthetic N-formyl-noratropine, noratropine 
red trace, N-formyl-noratropine blue trace. Right: direct infusion MS/MS spectra of 
N-formyl-noratropine. Inset right: assignment of fragment ion at m/z 138 
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